HealthDay on MSN1h
More Type 1 Diabetics Are Obese, Taking GLP-1 Drugs
Key Takeaways More people with type 1 diabetes are severely obese and using GLP-1 drugs for weight lossExperts are concerned ...
Le Lézard1h
SCORE analysis of semaglutide 2.4 mg demonstrated risk reduction in cardiovascular events in a real-world setting
Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults ...
Semaglutide 2.4 mg reduces burden of total cardiovascular events in people with established cardiovascular disease and overweight or obesity
A new sub-analysis of the SELECT trial data shows semaglutide 2.4 mg substantially reduces the burden of total cardiovascular ...
Explainer: Alarming rise in obesity cases weighing India down
The Lancet estimated that in 2021, India had the highest number of overweight or obese young people, surpassing China and the ...
Medical Dialogues20h
Obesity and Diabetes Linked to Increased Pancreatic Cancer Risk: UK Biobank Study
UK: A recent study based on the UK Biobank cohort suggests that general obesity and diabetes may contribute to a higher risk ...